Historical Valuation
Jupiter Neurosciences Inc (JUNS) is now in the Fair zone, suggesting that its current forward PS ratio of 34.26 is considered Fairly compared with the five-year average of -5.86. The fair price of Jupiter Neurosciences Inc (JUNS) is between 0.36 to 2.12 according to relative valuation methord.
Relative Value
Fair Zone
0.36-2.12
Current Price：1.03
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Jupiter Neurosciences Inc (JUNS) has a current Price-to-Book (P/B) ratio of 603.35. Compared to its 3-year average P/B ratio of 238.34 , the current P/B ratio is approximately 153.14% higher. Relative to its 5-year average P/B ratio of 238.34, the current P/B ratio is about 153.14% higher. Jupiter Neurosciences Inc (JUNS) has a Forward Free Cash Flow (FCF) yield of approximately -19.39%. Compared to its 3-year average FCF yield of -13.01%, the current FCF yield is approximately 49.05% lower. Relative to its 5-year average FCF yield of -13.01% , the current FCF yield is about 49.05% lower.
P/B
Median3y
238.34
Median5y
238.34
FCF Yield
Median3y
-13.01
Median5y
-13.01
Competitors Valuation Multiple
AI Analysis for JUNS
The average P/S ratio for JUNS competitors is 5.93, providing a benchmark for relative valuation. Jupiter Neurosciences Inc Corp (JUNS.O) exhibits a P/S ratio of 34.26, which is 477.2% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for JUNS
1Y
3Y
5Y
Market capitalization of JUNS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of JUNS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is JUNS currently overvalued or undervalued?
Jupiter Neurosciences Inc (JUNS) is now in the Fair zone, suggesting that its current forward PS ratio of 34.26 is considered Fairly compared with the five-year average of -5.86. The fair price of Jupiter Neurosciences Inc (JUNS) is between 0.36 to 2.12 according to relative valuation methord.
What is Jupiter Neurosciences Inc (JUNS) fair value?
JUNS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Jupiter Neurosciences Inc (JUNS) is between 0.36 to 2.12 according to relative valuation methord.
How does JUNS's valuation metrics compare to the industry average?
The average P/S ratio for JUNS's competitors is 5.93, providing a benchmark for relative valuation. Jupiter Neurosciences Inc Corp (JUNS) exhibits a P/S ratio of 34.26, which is 477.20% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Jupiter Neurosciences Inc (JUNS) as of Jan 09 2026?
As of Jan 09 2026, Jupiter Neurosciences Inc (JUNS) has a P/B ratio of 603.35. This indicates that the market values JUNS at 603.35 times its book value.
What is the current FCF Yield for Jupiter Neurosciences Inc (JUNS) as of Jan 09 2026?
As of Jan 09 2026, Jupiter Neurosciences Inc (JUNS) has a FCF Yield of -19.39%. This means that for every dollar of Jupiter Neurosciences Inc’s market capitalization, the company generates -19.39 cents in free cash flow.
What is the current Forward P/E ratio for Jupiter Neurosciences Inc (JUNS) as of Jan 09 2026?
As of Jan 09 2026, Jupiter Neurosciences Inc (JUNS) has a Forward P/E ratio of -4.81. This means the market is willing to pay $-4.81 for every dollar of Jupiter Neurosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Jupiter Neurosciences Inc (JUNS) as of Jan 09 2026?
As of Jan 09 2026, Jupiter Neurosciences Inc (JUNS) has a Forward P/S ratio of 34.26. This means the market is valuing JUNS at $34.26 for every dollar of expected revenue over the next 12 months.